Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, May 4, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed patient enrollment ahead of schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is […]
Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, April 5, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after […]
Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions
July 13th, New York, NY Poignantly crafted from the clearest crystal, the Retina Innovation Award that now claims pride of place in Endogena Therapeutics’ trophy cabinet represents how far the company has come in developing a potential new treatment for people losing their sight because of retinitis pigmenosa (RP). More than 350 international delegates including clinicians, […]